{"contentid": 488038, "importid": NaN, "name": "Trial of Libtayo stopped early on strong Phase III data", "introduction": "Having just last month notched up two US regulatory approvals for Libtayo (cemiplimab), French pharma major Sanofi and US biotech Regeneron today had more positive news on their PD-1 inhibitor.", "content": "<p>Having just last month notched up two US regulatory approvals for Libtayo (cemiplimab), French pharma major Sanofi (Euronext: SAN) and US biotech Regeneron (Nasdaq: REGN) today had more positive news on their PD-1 inhibitor.</p>\n<p>They said the Phase III study as a monotherapy compared to chemotherapy in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic, will be stopped early based on a unanimous recommendation by the Independent Data Monitoring Committee (IDMC), and the data will form the basis of regulatory submissions in 2021</p>\n<p>&ldquo;Libtayo monotherapy is the first medicine to demonstrate an improvement in overall survival in women with recurrent or metastatic cervical cancer following progression on platinum-based chemotherapy in a Phase III trial,&rdquo; said Dr Krishnansu Tewari, Professor and director of the Division of Gynecologic Oncology at the University of California, Irvine and a trial investigator, adding: &ldquo;This landmark clinical achievement will bring hope to women with advanced cervical cancer who are often younger than patients with other cancers. This is reflected in the trial where the average age was 51.&rdquo;</p>\n<p>This is the largest Phase III randomized clinical trial in advanced cervical cancer and included women (median age: 51 years) with either squamous cell carcinoma or adenocarcinoma. Patients were randomized to receive Libtayo monotherapy (350mg every three weeks) or an investigator&rsquo;s choice of commonly used chemotherapy (pemetrexed, vinorelbine, topotecan, irinotecan or gemcitabine).&nbsp;</p>\n<h2><strong>Regulatory history</strong></h2>\n<p>Today&rsquo;s announcement follows the recent <a href=\"https://www.thepharmaletter.com/article/us-approval-for-libtayo-in-lung-cancer\">US approval of Libtayo monotherap</a>y for certain patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression.</p>\n<p>The FDA also recently authorized the use of Libtayo as the first immunotherapy indicated for patients with basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate, whose cancer is either locally advanced (full approval) or metastatic (accelerated approval).</p>\n<p>In 2018, Libtayo was approved as the first systemic treatment for certain patients with advanced cutaneous squamous cell carcinoma (CSCC).</p>", "date": "2021-03-15 12:19:00", "meta_title": "Trial of Libtayo stopped early on strong Phase III data", "meta_keywords": "Sanofi, Regeneron, Libtayo, Phase III, Cancer, Cervical, IDMC, Recommendation, Halted", "meta_description": "Trial of Libtayo stopped early on strong Phase III data", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-15 12:17:00", "updated": "2021-03-15 12:28:32", "access": NaN, "url": "https://www.thepharmaletter.com/article/trial-of-libtayo-stopped-early-on-strong-phase-iii-data", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "sanofi-regeneron-big.jpg", "image2id": "sanofi-regeneron-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Drug Trial, Research", "geography_tag": "France, USA", "company_tag": "Regeneron Pharmaceuticals, Sanofi", "drug_tag": "Libtayo", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-15 12:19:00"}